Work

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.4509

Authors: B. Rini, O. Rixe, R. Bukowski, M. D. Michaelson, G. Wilding, G. Hudes, O. Bolte, H. Steinfeldt, S. D. Reich, R. Motzer

Institutions: Fox Chase Cancer Center, Cleveland Clinic, University of Wisconsin–Madison, University of California, San Francisco, Pfizer (United States), Medizinische Hochschule Hannover, Pitié-Salpêtrière Hospital

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2206164324

Cites:

Cited by: 148

Related to: 10